Dowling & Yahnke LLC increased its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,072 shares of the biopharmaceutical company’s stock after acquiring an additional 155 shares during the period. Dowling & Yahnke LLC’s holdings in Celgene Corporation were worth $3,516,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in CELG. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the first quarter worth about $118,000. Acropolis Investment Management LLC acquired a new position in Celgene Corporation during the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares during the period. Rational Advisors LLC acquired a new position in Celgene Corporation during the second quarter worth about $156,000. Finally, Oakworth Capital Inc. grew its holdings in Celgene Corporation by 11.7% during the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 127 shares during the period. 79.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (NASDAQ CELG) opened at 136.71 on Tuesday. The firm has a market capitalization of $106.96 billion, a price-to-earnings ratio of 42.34 and a beta of 1.89. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $147.17. The company has a 50-day moving average price of $141.03 and a 200 day moving average price of $130.15.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the prior year, the firm posted $1.44 earnings per share. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. Equities research analysts expect that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on CELG shares. BidaskClub raised Celgene Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Leerink Swann reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Thursday, June 22nd. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. BTIG Research lowered Celgene Corporation from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Finally, Vetr raised Celgene Corporation from a “hold” rating to a “strong-buy” rating and set a $149.76 target price on the stock in a report on Tuesday, July 4th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $150.80.

In related news, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold 46,233 shares of company stock valued at $6,268,259 over the last three months. Insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/17/celgene-corporation-celg-shares-bought-by-dowling-yahnke-llc.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.